Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates

Core Insights - Haemonetics reported quarterly earnings of $1.27 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and up from $1.12 per share a year ago [1] - The earnings surprise was +13.39%, with the company having surpassed consensus EPS estimates three times in the last four quarters [2] Financial Performance - The company posted revenues of $327.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.22%, but down from $345.51 million year-over-year [3] - Haemonetics has also topped consensus revenue estimates three times over the last four quarters [3] Stock Performance and Outlook - Haemonetics shares have declined approximately 35% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [4] - The current consensus EPS estimate for the upcoming quarter is $1.28 on revenues of $330.9 million, and for the current fiscal year, it is $4.80 on revenues of $1.3 billion [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges ahead [9]